Glenmark Pharma rose almost 4.5% to Rs.626.65 during intra day and remains in the green. Its 52-week high and low stands at Rs.993 and Rs.567.95 respectively.

There is good news and that from two regulatory bodies. The UK drug regulator renewed its manufacturing certificate for the Baddi unit. And the Czech regulator renewed the manufacturing certificate for its Fibichova unit.

This is a step in the right direction for a company which is moving from being a mere generic player to include specialty and innovative products. It plans to lay emphasis on R&D and will be spending around 12% of its revenue on the same